A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in ...

This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, ...

Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published its 2024 Annual Report along with the invitation to its first Annual General Meeting which will be held on ...

Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess ® (RelabotulinumtoxinA) highlighting its rapid onset of action as ...

Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions ...

Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA ...

MIAMI, March 17, 2025 /PRNewswire/ -- Galderma's leading acne care line, Differin, is expanding its presence on gaming platforms as the first in its category to launch on Roblox. The brand's ...

Australia’s booming $4 billion injectables market is driven by doctors issuing scripts via telehealth in consults that ...

In a report released today, Cedric Besnard from Citi maintained a Buy rating on Galderma Group AG (GALD – Research Report), with a price target ...

Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.